Local News
Adults from the area take part in a “game-changing” Alzheimer’s medication trial
Rochester, New York – A small group of local adults took part in a study for a brand-new Alzheimer’s medication.
Lecanemab, the medication, was evaluated in phase 3 international clinical trial. According to drug producers, a monoclonal antibody treatment for Alzheimer’s disease significantly delayed the rate of cognitive loss compared to a placebo.
This is a significant step towards postponing the disease’s consequences, according to Dr. Anton Porsteinsson, Director of the University of Rochester Alzheimer’s Disease Care.
“What the families say, I want to keep them the way they are now for as long as possible so that we can enjoy the time that we have together and delay the time until they need all of the constant supervision,” said Dr. Porsteinsson.
By the end of March 2023, the trial’s participating companies hope to receive regulatory approval from the United States.
-
Local News6 days ago
Reducing illicit ATV and dirt bike activity in Irondequoit; providing an update on the special police detail
-
Local News2 weeks ago
Rochester Board of Education vice president under investigation for alleged threat
-
New York2 weeks ago
Push grows to expand New York’s liquor shipment, container laws
-
Local News1 week ago
Genesee Brewery’s $50 million investment enables the construction of a new, “state-of-the-art” packaging factory
-
Local News2 weeks ago
To support kids who need a wish, more than 275 people attend the Make-A-Wish gala
-
Local News2 weeks ago
Schumer declares $400 million in federal funding for religious institutions’ protection
-
Local News1 week ago
A judge strikes down the New York abortion rights amendment on November ballots
-
Local News1 week ago
Students from U of R gather as the institution suggests probable sanctions due to on-campus demonstrations